Sulodexide in the Treatment of Chronic Primary Venous Disease of the Lower Extremities

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

290 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-25

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study compares the efficacy and safety of sulodexide (Vessel) to placebo in patients with chronic venous disease of the lower extremities.

The primary hypothesis is that more patients will achieve a decrease in rVCSS score of at least 4 points with sulodexide than with placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Study of Reducing Adverse Effects After Radiofrequency Ablation Combined With Sclerotherapy

NCT05654233

Vascular Diseases, Peripheral Venous Insufficiency of Leg Varicose Veins of Lower Limb

UNKNOWN NA

Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon

NCT01477281

Chronic Venous Insufficiency Disease

UNKNOWN PHASE3

Efficacy of Complex Decongestive Therapy (CDT) in Patients With Venous Insufficiency: a Experimental Study

NCT06231940

Lymphatic Edema Cellulitis of Leg Vein Disease

COMPLETED NA

Clinical Trial of Aesculus Hippocastanum and Associations Versus Diosmina and Hesperidina in Chronic Venous Insuficiency

NCT06579482

Chronic Venous Insufficiency

COMPLETED PHASE4

Radiofrequency Ablation vs Laser Ablation of the Incompetent Greater Saphenous Vein

NCT02236338

Chronic Venous Insufficiency

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chronic venous disease (CVD) prevalence is increasing in developed countries. The frequency reported in different sources ranges between 10 and 50% of the population and its rise is expected resulting from the overall aging of the population. The most common symptoms of Chronic venous disease of lower extremities include, increased limb fatigue, heaviness and swelling, pain, cramps, itching, and trophic skin changes that can result in a venous ulcer. CVD has a significant impact on the patient's quality of life and their work productivity.

Conservative treatment consists of lifestyle measures, compression therapy and use of venoactive drugs (venopharmaceuticals). Venoactive drugs are a heterogenous group of compounds with various mechanisms of action, such as increasing venous wall tonus, reducing capillary fragility and permeability, increasing capillary resistance, and improving lymphatic drainage. The goal of the treatment is anti-oedematous action, improvement of trophism of affected tissues, reduction of subjective symptoms, swelling of the limbs and affecting related trophic skin changes which leads to the increase of quality of life.

Sulodexide has protective effect on the endothelium, antithrombotic, fibrinolytic and anti-inflammatory effects. In the last 20 years, it has been well established in the common practice and its efficacy and safety have been demonstrated notably in the treatment of venous diseases such as post-thrombotic syndrome of the lower extremities, secondary prevention of deep and superficial venous thrombosis, supportive treatment of leg venous ulceration, ischemic disease of the lower limbs; symptomatic therapy of intermittent claudication, treatment of diabetic ulcers and microcirculation disorders of various aetiology. Patients with CVD were shown to respond quickly to sulodexide therapy in single arm observational studies. Sulodexide seems to provide both symptomatic and causal therapy. The aim of the present study is to provide the first high-level (causal) evidence on the efficacy and safety of sulodexide across the whole spectrum of patients suffering from symptomatic primary CVD (CEAP classification C2S to C6S).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Venous Disease Chronic Insufficiency Venous

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

two arms - the sulodexide arm compared to placebo arm

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sulodexide arm

Name: Vessel (medicinal product registered in Italy) Dosage form: soft capsules Active substance: sulodexidum 250 LSU Dosage: 2 x 2 soft capsules daily (oral use), in line with the labelled posology (500 LSU twice a day) Duration: 24 ± 4 weeks

Group Type EXPERIMENTAL

Vessel

Intervention Type DRUG

Sulodexide has protective effect on the endothelium, antithrombotic, fibrinolytic and anti-inflammatory effects. In the last 20 years, it has been well established in the common practice and its efficacy and safety have been demonstrated notably in the treatment of venous diseases such as post-thrombotic syndrome of the lower extremities, secondary prevention of deep and superficial venous thrombosis, supportive treatment of leg venous ulceration, ischemic disease of the lower limbs; symptomatic therapy of intermittent claudication, treatment of diabetic ulcers and microcirculation disorders of various aetiology. Patients with CVD were shown to respond quickly to sulodexide therapy in single arm observational studies. Sulodexide seems to provide both symptomatic and causal therapy.

Placebo arm

Dosage form: soft capsules Appearance: undistinguishable from the active Dosage regimen: 2 x 2 soft capsules daily Duration of placebo intake: a total of 24 ± 4 weeks

Group Type PLACEBO_COMPARATOR

Placebo

* Use of a drug with venoactive effect in the last month
* Regular use of compression therapy or use of mechanical devices for reduction of oedema in the last month
* Heart Failure as per NYHA III and IV, congestive heart failure with peripheral oedemas
* Chronic kidney disease with GF \< 30 ml/min (\< 0,5 ml/s) and/or proteinuria \> 0,5 g/24 hours, nephrotic syndrome, renal oedemas
* Advanced liver disease (Child-Pugh B and C or laboratory values of ALT or AST more than 3 times upper limit of normal range)
* Deep venous thrombosis lower limb thrombosis and / or documented residual venous obstruction or deep venous reflux due to post-thrombotic changes in the deep venous system
* Superficial venous thrombosis of the lower limbs in the previous 6 months
* Congenital venous / venolymphatic venous malformation
* Neuropathy of any aetiology
* Diabetic foot syndrome
* Refractory (uncontrollable) arterial hypertension (inability to achieve therapeutically systolic blood pressure ≤ 160 mmHg or diastolic blood pressure ≤ 100 mmHg)
* Symptomatic ischemic disease of lower limbs
* Lymphoedema: primary, posttraumatic, postoperative, post-radiation, malignant
* Manual/instrumental lymphatic drainage in the last 6 months
* Invasive procedure on the lower limbs in the last 6 months
* Trauma of the lower extremity that has not fully healed
* Use of oral/parenteral anticoagulants, dual antiplatelet therapy, diuretics, corticosteroids, oestrogens, or progesterone and its derivates
* Chronic pain treatment ≥ 14 days
* Psychopharmaceuticals affecting fluid retention (antipsychotics, combined antidepressants)
* Pathologic obesity (BMI \> 40 kg/m2)
* The patient is currently enrolled in another interventional or non-interventional study
* Contraindications to the administration of sulodexide according to IB (haemorrhagic diathesis, hypersensitivity to the drug substance or any of the excipients, heparin, heparinoids or other glycosaminoglycans (GAGs), etc.)
* Patients with active malignant disease or malignant disease in remission for less than 5 years
* Pregnancy
* Breastfeeding

* Clinically significant progression of the investigated condition, which requires urgent or early invasive therapy (as assessed by the investigating physician)
* Onset of any condition requiring initiation of the not permitted medication/treatment
* Serious adverse reactions
* Pregnancy

Compression therapy can be initiated anytime during the trial participation in case that patient experiences worsening of the rVCSS score of at least 4 points compared to baseline AND the treating physician decides to prescribe such regimen. Certified/notified compression stockings of class II (23-32 mmHg) based on circular knit are allowed. Patients initiating compression therapy are not excluded but the stocking need to be taken off a day before the scheduled study visit. The treatment allocation in patients initiating compression therapy remain blinded.

In case compression therapy is initiated during study participation, information about the date of initiation, type and adherence is collected in the following visits.

If sufficient proportion of subjects is switched to compression therapy, compression therapy will be tested as effect modifier across CEAP classes.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No